Jeffrey S. Moffit

588 total citations
16 papers, 451 citations indexed

About

Jeffrey S. Moffit is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Jeffrey S. Moffit has authored 16 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Jeffrey S. Moffit's work include Drug Transport and Resistance Mechanisms (4 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Testicular diseases and treatments (3 papers). Jeffrey S. Moffit is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Testicular diseases and treatments (3 papers). Jeffrey S. Moffit collaborates with scholars based in United States, France and United Kingdom. Jeffrey S. Moffit's co-authors include Kim Boekelheide, John M. Sedivy, Jan Kłysik, Susan J. Hall, Bronwyn Bryant, José E. Manautou, Curtis D. Klaassen, Steven J. Theroux, Lauren M. Aleksunes and George L. Scheffer and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Toxicology and Applied Pharmacology.

In The Last Decade

Jeffrey S. Moffit

16 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey S. Moffit United States 11 218 95 74 66 59 16 451
Jiuan-Jiuan Hwang Taiwan 12 304 1.4× 61 0.6× 94 1.3× 22 0.3× 104 1.8× 15 596
Marine Baptissart France 14 265 1.2× 141 1.5× 215 2.9× 39 0.6× 41 0.7× 24 643
Jean‐Marc Lobaccaro France 10 184 0.8× 72 0.8× 106 1.4× 28 0.4× 25 0.4× 12 449
Se-Ra Lee South Korea 13 199 0.9× 21 0.2× 49 0.7× 34 0.5× 25 0.4× 35 407
Eunsook Park South Korea 15 214 1.0× 55 0.6× 35 0.5× 30 0.5× 18 0.3× 29 444
Aurélie Vega France 11 176 0.8× 87 0.9× 127 1.7× 20 0.3× 24 0.4× 11 450
Nobuyoshi Chiba Japan 9 355 1.6× 54 0.6× 36 0.5× 21 0.3× 27 0.5× 13 686
Victor K. Khor United States 10 226 1.0× 41 0.4× 42 0.6× 16 0.2× 32 0.5× 13 632
Anila Dwivedi India 16 205 0.9× 147 1.5× 45 0.6× 25 0.4× 43 0.7× 32 549
Dong Hou China 11 274 1.3× 59 0.6× 86 1.2× 19 0.3× 88 1.5× 12 489

Countries citing papers authored by Jeffrey S. Moffit

Since Specialization
Citations

This map shows the geographic impact of Jeffrey S. Moffit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey S. Moffit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey S. Moffit more than expected).

Fields of papers citing papers by Jeffrey S. Moffit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey S. Moffit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey S. Moffit. The network helps show where Jeffrey S. Moffit may publish in the future.

Co-authorship network of co-authors of Jeffrey S. Moffit

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey S. Moffit. A scholar is included among the top collaborators of Jeffrey S. Moffit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey S. Moffit. Jeffrey S. Moffit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Moffit, Jeffrey S., et al.. (2025). Nonclinical strategies and considerations to enable the redosing of gene therapies. Molecular Therapy — Methods & Clinical Development. 33(3). 101520–101520. 1 indexed citations
2.
MacDonald, Kelvin D., et al.. (2024). Current landscape of cystic fibrosis gene therapy. Frontiers in Pharmacology. 15. 1476331–1476331. 6 indexed citations
3.
Moffit, Jeffrey S., Diann Blanset, Jessica Lynch, et al.. (2022). Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies. Human Gene Therapy. 33(21-22). 1126–1141. 11 indexed citations
4.
Bursavich, Matthew G., Bryce A. Harrison, Lori Hrdlicka, et al.. (2021). Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator. Journal of Medicinal Chemistry. 64(19). 14426–14447. 8 indexed citations
5.
Dere, Edward, Daniel J. Spade, Susan Hall, et al.. (2017). Identification of sperm mRNA biomarkers associated with testis injury during preclinical testing of pharmaceutical compounds. Toxicology and Applied Pharmacology. 320. 1–7. 6 indexed citations
6.
Bursavich, Matthew G., Bryce A. Harrison, Lori Hrdlicka, et al.. (2017). Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer’s Disease. Journal of Medicinal Chemistry. 60(6). 2383–2400. 24 indexed citations
7.
Chapin, Robert E., Gerhard F. Weinbauer, Michael S. Thibodeau, et al.. (2013). Summary of the HESI Consortium Studies Exploring Circulating Inhibin B as a Potential Biomarker of Testis Damage in the Rat. Birth Defects Research Part B Developmental and Reproductive Toxicology. 98(1). 110–118. 10 indexed citations
8.
Moffit, Jeffrey S., et al.. (2013). Assessment of Inhibin B as a Biomarker of Testicular Injury Following Administration of Carbendazim, Cetrorelix, or 1,2‐Dibromo‐3‐Chloropropane in Wistar Han Rats. Birth Defects Research Part B Developmental and Reproductive Toxicology. 98(1). 17–28. 7 indexed citations
9.
Sasaki, Jennifer C., Robert E. Chapin, William J. Breslin, et al.. (2011). Incidence and nature of testicular toxicity findings in pharmaceutical development. Birth Defects Research Part B Developmental and Reproductive Toxicology. 92(6). 511–525. 30 indexed citations
10.
Leconte, Isabelle, Graham P. Bailey, Karen Davis‐Bruno, et al.. (2011). Value of juvenile animal studies. Birth Defects Research Part B Developmental and Reproductive Toxicology. 92(4). 292–303. 15 indexed citations
11.
Moffit, Jeffrey S., Petra Koza‐Taylor, Ricky D. Holland, et al.. (2007). Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate☆. Toxicology and Applied Pharmacology. 222(2). 169–179. 25 indexed citations
12.
Moffit, Jeffrey S., Bronwyn Bryant, Susan J. Hall, & Kim Boekelheide. (2007). Dose-Dependent Effects of Sertoli Cell Toxicants 2,5-Hexanedione, Carbendazim, and Mono-(2-ethylhexyl) phthalate in Adult Rat Testis. Toxicologic Pathology. 35(5). 719–727. 91 indexed citations
13.
Moffit, Jeffrey S., Kim Boekelheide, John M. Sedivy, & Jan Kłysik. (2007). Mice Lacking Raf Kinase Inhibitor Protein‐1 (RKIP‐1) Have Altered Sperm Capacitation and Reduced Reproduction Rates With a Normal Response to Testicular Injury. Journal of Andrology. 28(6). 883–890. 30 indexed citations
14.
Kłysik, Jan, Steven J. Theroux, John M. Sedivy, Jeffrey S. Moffit, & Kim Boekelheide. (2007). Signaling crossroads: The function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cellular Signalling. 20(1). 1–9. 83 indexed citations
15.
Moffit, Jeffrey S., Lauren M. Aleksunes, Jonathan Maher, et al.. (2006). Induction of Hepatic Transporters Multidrug Resistance-Associated Proteins (Mrp) 3 and 4 by Clofibrate Is Regulated by Peroxisome Proliferator-Activated Receptor α. Journal of Pharmacology and Experimental Therapeutics. 317(2). 537–545. 56 indexed citations
16.
Moffit, Jeffrey S., et al.. (2006). Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen. Toxicology. 230(2-3). 197–206. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiuan-Jiuan Hwang Breakdown of academic impact, for papers by Marine Baptissart Breakdown of academic impact, for papers by Jean‐Marc Lobaccaro Breakdown of academic impact, for papers by Se-Ra Lee Breakdown of academic impact, for papers by Eunsook Park Breakdown of academic impact, for papers by Aurélie Vega Breakdown of academic impact, for papers by Nobuyoshi Chiba Breakdown of academic impact, for papers by Victor K. Khor Breakdown of academic impact, for papers by Anila Dwivedi Breakdown of academic impact, for papers by Dong Hou
Rankless by CCL
2026